|Title:||Consensus Statement on Antimicrobial Therapy of Intra-Abdominal Infections in Asia||Authors:||Hsueh, Po-Ren
Hawkey, Peter Michael
|Keywords:||intra-abdominal infections;antimicrobial therapy;Asia;consensus||Issue Date:||2007||Journal Volume:||v.30||Journal Issue:||n.2||Start page/Pages:||129-133||Source:||INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS||Abstract:||
The selection of antimicrobial agents in the 2006 Guidelines (consensus statement) on Empiric Therapy for Complicated Intra-Abdominal Infections ( IAIs) in Asia was based on resistance and epidemiological data from the Asian region. In these 2006 guidelines, single agent therapy using the beta-lactam/beta-lactamase inhibitors ampicillin/sulbactam or cefoperazone -sulbactam is recommended for mild-to- moderate cases, while piperacillin- tazobactam is recommended for high-severity cases. When using carbapenems, ertapenem is recommended for mild-to-moderate cases, while imipenem and meropenem are recommended for high-severity cases. For combination regimes , two types of agents are recommended: cephalosporin-based and monobactam- based. For mild-to- moderate cases, a third generation cephalosporin plus metronidazole is recommended. For high-severity cases, a third or fourth generation cephalosporin plus metronidazole+ /- amikacin is recommended. For the monobactam-based regimen , aztreonam plus metronidazole is recommended for high- severity cases only. (c) 2007 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
|Appears in Collections:||醫學系|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.